USA flag logo/image

An Official Website of the United States Government

Accelerated Discovery and Development of New Pain Therapeutics

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85934
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
NS059140
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AESTUS THERAPEUTICS, INC.
AESTUS THERAPEUTICS, INC. 675 US Highway One North Brunswick, NJ -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Accelerated Discovery and Development of New Pain Therapeutics
Agency: HHS
Contract: 1R43NS059140-01A1
Award Amount: $198,960.00
 

Abstract:

DESCRIPTION (provided by applicant): More than 25 million people in the United States suffer from neuropathic pain. Currently available drugs include opioids, anti-epileptics, topicals such as lidocaine, NMDA antagonists, and tricyclic antidepressants, no ne of which achieve clinical significance greater than 50%. To address this problem of significant clinical need and poor clinical significance, new mechanisms of action must be identified for pain therapeutics. Genome-scale technologies such as gene expre ssion microarray data have contributed an exponential amount of diverse biological information available to the public. The goal of this project is to analyze this data to generate new understanding of underlying biological mechanisms which can lead direct ly to a marketable pain therapeutic. Recently, many researchers have extracted biological pathway information from gene expression microarray experiments performed in-house. In order to take advantage of the much more diverse information contained in publi c microarray data, this proposal tests the feasibility of new methods to combine unstructured information from multiple public datasets to derive new insight on biological pathways underlying neuropathic pain. Newly associated pathway information is used t o identify therapeutics which affect the identified pathway and which have been tested in man, but whose mechanism of action has not been previously associated with pain. The identified drugs will be validated in animal models. Since the identified therape utic by definition is an IND, successful demonstration of efficacy in animals will lead directly to clinical phase 2 proof of concept in man during the SBIR Phase II renewal. Thus this project proposes a method to significantly reduce drug discovery and ea rly development risk by triaging public gene expression data to progress directly to product identification and late stage clinical studies for pain therapeutics with new mechanisms of action. Neuropathic pain patients tend to become globally disabled and are heavy users of healthcare resources. Current therapies have limited efficacy and issues with side effects. The present project proposes a method to significantly reduce drug discovery and early development risk by triaging public gene expression data t o progress directly to product identification and late stage clinical studies for pain therapeutics with new mechanisms of action.

Principal Investigator:

Lillian W. Chiang
7342490690
LILLIAN@AESTUSTX.COM

Business Contact:

Tage Honore
thonore@aestustherapeutics.com
Small Business Information at Submission:

AESTUS THERAPEUTICS, INC.
AESTUS THERAPEUTICS, INC. 675 US Highway One North Brunswick, NJ 08540

EIN/Tax ID: 156256016
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No